

International Coalition of Medicines Regulatory Authorities (ICMRA)

From Crisis Management to better Regulation

25th DGRA Annual Congress - May 4th and 5th, 2023 - Bonn

Presented by Riccardo Luigetti International Affairs EMA





The ICMRA (1)

A global coalition of Medicines Regulatory Authorities, working together

- Strategic directions
- Information sharing
- Crisis response
- Regulatory science
- Enhanced communication



1 International Coalition of Medicines Regulatory (ICMRA) - DGRA Annual Congress May 2023

Classified as public by the European Medicir



The ICMRA (2)

Global participation at HoAs level

- 40 participating authorities including WHO
- EMA chairs since 2017

Governance

- Chair: EMA
- Vice-Chairs: MHLW/PMDA; ANVISA
- Executive Committee
- Members, Associate Members, Observers





https://www.icmra.info/drupal/en/participatingRegulatoryAuthorities

2 International Coalition of Medicines Regulatory (ICMRA) - DGRA Annual Congress May 2023

Classified as public by the European Medicir



ICMRA Strategic Framework and Related Activities ICMRA Leaders will respond to current and emerging human medicine regulatory and safety challenges globally, strategically and in a transparent manner **Enable and Facilitate** Inform/Engage Strategic Leadership STRATEGIC OBJECTIVES Strategic leadership by identifying shared Identify and support global collaboration needs Communicate to stakeholders ICMRA's goals and mechanisms, including the sharing of regulatory challenges and bring together and activities, and facilitate the leveraging of initiatives/enablers to effectively information and expertise to strengthen existing initiatives to address evolving respond regulatory global initiatives regulatory challenges ✓ identify shared regulatory challenges and exercise 1 enable regulatory systems which facilitate improved leverage and influence existing initiatives to ~ strategic leadership by taking a collective approach access to and availability of safe, efficacious and advance common priorities (e.g. PIC/S, IPRF, IGDRP, as a Coalition to avoid duplication of activities among quality medicines ICH, APEC etc.) enable innovation including novel regulatory ✓ engage stakeholders (e.g., industry and nonregulatory authorities 1 establish more effective channels of information approaches and the advancement of regulatory governmental organizations) in addressing sharing and communication science regulatory challenges promote the strengthening and alignment of 1 create a framework for leadership, governance and ✓ foster the development of mechanisms and 1 WHAT WE DO action for shared regulatory concerns systems to facilitate regulatory collaboration and regulatory systems across medicines regulatory ~ promote the leveraging of regulatory authorities' modernisation, including work and information authorities in developing countries by facilitating collective resources, including the sharing of their involvement in regulatory initiatives sharing knowledge, work products, expertise, experience ~ promote better informed risk-based allocation of and best practices regulatory resources ~ prompt identification of and coordinated 1 facilitate the wider exchange of information multilateral response to emerging global issues promote convergence of regulatory frameworks, 1 engage as a Coalition in strategic partnerships on ~ where appropriate issues of global impact/concern (e.g. WHO) ✓ promote the coordination of training initiatives and

- 3 International Coalition of Medicines Regulatory (ICMRA) DGRA Annual Congress May 2023
 - f Medicines Regulatory (ICMRA) DGRA Annual Congress May

tools

EUROPEAN MEDICINES AGENCY

Why do we need an ICMRA

- Growing complexity of medicinal products and their ingredients
- Growing complexity and globalization of supply-chains
- Growing number of international regulatory initiatives, lack of integration and strategic oversight
- Need to control regulatory public expenditures
- Need for alignment of regulatory practice and activities
- > Global health crisis need global response



4 International Coalition of Medicines Regulatory (ICMRA) - DGRA Annual Congress May 2023

Classified as public by the European Medic



Historical background

May 2012

• High-level seminar hosted by Brazil before the 65th World Health Assembly in Geneva, highlighting importance of better coordinating international cooperation among MRAs

October 2012

• Meetings of MRA executives held in the margins of the WHO International Conference of Drug Regulatory Authorities

November 2012

• Seventh Heads of MRAs Summit in Manaus expressed support for creation of ICMRA

December 2013

• Eighth Heads of MRA Summit in Amsterdam establishes ICMRA

Classified as public by the European Medi





ICMRA way of working

Summit

- Strategic discussion at HoAs level
- Informal setting

Regulatory Forum

• Deep Dive on specific topics

Informal Networks

- Exchange of information
- Advice to network

Workshops

• Discussion among regulators or with stakeholders

Ad hoc activities



6 International Coalition of Medicines Regulatory (ICMRA) - DGRA Annual Congress May 2023

Classified as public by the European Medicine



Summit November 2022 – Dublin - Looking into the future

Regulators as main source of information, fight misinformation, hesitancy



- 1) Challenging Our thinking on Ph.Vig.
- 2) Innovation and the Future Opportunities
- 3) Living with COVID-19

Equitable access to medicines

Innovation: enormous opportunities, challenges for regulators

7 International Coalition of Medicines Regulatory (ICMRA) - DGRA Annual Congress May 2023

Classified as public by the Eur



ICMRA Regulatory Forum



Formerly COVID-19 Policy TC

Deep Dive on specific topics e.g.:

 Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), from Critical Path Institute

8 International Coalition of Medicines Regulatory (ICMRA) - DGRA Annual Congress May 2023

Classified as public by the European Medicines

EUROPEAN MEDICINES AGENCY

ICMRA: Main Activity Areas

Communication

Innovation

Artificial Intelligence

Real Word Evidence

Public Health Emergencies Clinical Trials

COVID-19 Vaccine Pharmacovigilance

Anti Microbial Resistance


Pharmaceutical Quality Knowledge Management System ICMRA has been extremely important during the pandemic, allowing global exchange of information and work sharing among regulators

> With the pandemic easing, ICMRA is rationalising its processes and rethinking its priorities

9 International Coalition of Medicines Regulatory (ICMRA) - DGRA Annual Congress May 2023

Classified as public by the Eu





- Quick exchange of information
- Regulatory Cooperation
- Coordinated actions globally
- ICMRA is now working towards preparedness for future crises, lesson learnt and applying pandemic agilities and flexibilities to routine, post-pandemic activities

Classified as public by the European Medicine



EUROPEAN MEDICINES AGENCY

¹⁰ International Coalition of Medicines Regulatory (ICMRA) - DGRA Annual Congress May 2023



The Covid-19 Vaccines Pharmacovigilance Network

Information Sharing, advice to network during the pandemic

Huge network of regulators from all the world regions

- Real-time sharing of information and experiences
- Quicker identification of potential signals
- Collaboration on important safety signals
- Simulation exercise
- ICMRA/WHO Vaccines Confidence Statement
- Common approaches
- Reduced duplications
- Regulatory decisions supported by global data



¹¹ International Coalition of Medicines Regulatory (ICMRA) - DGRA Annual Congress May 2023

Classified as public by the European Medicines

The Public Health Emergency Clinical Trials Working Group

Preparing for the Future

- Reflection Paper to enable implementation of multinational/multiregional platform clinical trials during Public Health Emergencies
- Key considerations for protocol elements that support initiation and conduct of platform clinical trials during Public Health Emergencies
- Facilitate use of core protocol elements for multinational/multiregional platform trials of vaccines and therapeutics in a cross-border public health emergency context, with COVID-19 as an initial model
- Shared understanding of these protocol elements to support global platform trials to be approved as well as implemented efficiently in more than one territory

Classified as public by the European Medici




EUROPEAN MEDICINES AGENCY





The Pharmaceutical Quality Knowledge Management System (PQKMS) Working Group (1)

Leveraging lesson learnt during the pandemic to improve routine processes



Classified as public by the European Medic



The Pharmaceutical Quality Knowledge Management System (PQKMS) Working Group (2)

ICMRA providing strategic vision and coordination to work progressed at existing organisations (ICH, IPRP, PIC/S)

Objectives:

- Develop framework for collaborative PAC assessment and hybrid inspections
- Identify misalignments, differences, and areas for alignment across regions
- Pilot submission of the same CMC information to multiple regulators for the same product and manufacturing facility

Classified as public by the European Medicines

• Increase confidence among regulatory authorities and among regulators and pharmaceutical industry

¹⁴ International Coalition of Medicines Regulatory (ICMRA) - DGRA Annual Congress May 2023



The Pharmaceutical Quality Knowledge Management System (PQKMS) Working Group (3)

Classified as public by the European Medic

- Joint Reflection Paper: ICMRA, ICH, IPRP, PIC/S
- Collaborative pilots:
 - Collaborative Post-Approval Changes
 Assessment Pilot
 - Collaborative Hybrid Inspections Pilot



- Cross-organisational collaboration on Unique Identifiers for manufacturers
- ICH Workplan
 - CTD, new GL on Structure of Product Submission
- IPRP Workplan
 - Surveys (Quality Assessment Tool, ICH Q12), Analysis (PAC/Variations)
- PIC/S Workplan
 - Training (PQS assessment), promoting GMP reliance, Data format for inspection report



Key Messages

The pharmaceutical sector is globalised and extremely complex

Future Public Health emergencies are likely to be global

No regulator can fulfil its role on its own any more; need for cooperation, worksharing, reliance

Global regulatory strategies are necessary

ICMRA role is strategic, not operational, it will leverage existing regulatory organisations/initiatives to operationalize its strategies



Classified as public by the European Medicin



Any questions?

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Telephone +31 (0)88 781 6000

Send us a question Go to www.ema.europa.eu/contact



Classified as public by the European Medicines Agency